Short communication

Effects of the COVID-19 pandemic on breast cancer screening in Taiwan

Huei-Yi Tsai a, b, Yu-Ling Chang c, Cheng-Ting Shen d, Wei-Shiuan Chung b, e, Hui-Ju Tsai d, Fang-Ming Chen f, g, h, *

a Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (No.100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City, 80708, Taiwan
b Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
c Cancer Center, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
d Department of Family Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
e Department of Radiology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
f Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
g Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
h Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

A R T I C L E I N F O

Article history:
Received 3 July 2020
Received in revised form 23 August 2020
Accepted 24 August 2020
Available online 3 September 2020

Keywords:
Breast cancer screening
COVID-19
Mammography
Outreach

A B S T R A C T

The breast cancer screening program has continued in Taiwan during the COVID-19 pandemic. Our nationwide data showed that the total number of screenings decreased by 22.2%, which was more pronounced for in-hospital examinations (−37.2%), while outreach showed a 12.9% decrease. This decline in screening participation happened at all levels of hospitals, more significantly at the highest level. Our report revealed that outreach services could maintain relatively stable breast cancer screening under this kind of public health crisis. Building a flexible, outreach system into the community might need to be considered when policymakers are preparing for future possible pandemics.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Regular breast cancer screening can reduce breast cancer deaths by 60% within 10 years after diagnosis [1]. Many countries have implemented breast cancer screening programs for decades; however, since the outbreak of the coronavirus disease-2019 (COVID-19) [2], routine screening has been postponed in many areas for prevention of spread of infection or for preservation of healthcare capacity [3,4].

The Health Promotion Administration of Taiwan decided to continue the cancer screening program because the COVID-19 infection has been relatively well-controlled in Taiwan [5,6]. For safe mammography examination, recommendations such as screening the participants for COVID-19 by symptoms and TOCC histories (travel, occupation, contact, and cluster), keeping social distance between participants, using personal protective equipment, and cleaning and disinfecting the examination room and mammography equipment were followed, and up to June 28, no COVID-19 infection had occurred in Taiwan due to mammography examination.

For promotion of in-hospital breast cancer screening in Taiwan, hospitals use posters, in-hospital broadcast, and out-patient department referral. District public health centers arrange outreach screening sessions and telephone eligible women in their district to encourage enrolment. During the pandemic, hospitals have been free to make their own screening policies, while district public health centers have decided on whether outreach sessions are held as scheduled or postponed, and eligible women are free to choose when and where to receive regular screening.

The aim of this report is to present our experience of breast
cancer screening during the COVID-19 pandemic using nationwide data.

2. Materials and methods

2.1. The breast cancer screening program

The Taiwan government started a nation-wide breast cancer screening program in 1999. Women aged 45–69 years are encouraged to have a government-subsidized mammography every two years, and women aged 40–44 years with second-degree relatives ever diagnosed with breast cancer are also included. The Ministry of Health and Welfare has provided special funding to hospitals-based outreach using mobile mammography units. A mobile mammography unit includes mammography equipment in a van and certificated radiographers who work together with physicians, nurses, and administration staff to provide community-based adult health examinations as well as cancer screening. According to the Health Promotion Administration Annual Report 2019 [7], the latest reported number of breast cancer screenings is 860,000 in 2018 and the screening rate is 39.9%.

2.2. Screening data

A national screening database is available for data mining and here we report the numbers of screenings and recall rates for January—April 2020, compared to those of the same period in 2019. There are four levels in the hierarchy of hospitals in Taiwan, being medical centers, regional hospitals, local hospitals, and clinics. Data has been stratified by the level of hospitals as well as by location where the mammography was carried out (in-hospital or outreach) and age of participants.

2.3. Statistics

The two-sample test for proportion was used to examine the differences of screening rates and recall rates in the two years selected for study, while the chi-square test was used to examine the relationship between the variables with stratified data and the screenings, with \( p < .05 \) being defined as statistically significant.

3. Results

Table 1 shows the overall conditions in 2019 and 2020, where the total number of screenings decreased by 22.2%. The decline was more pronounced for in-hospital examinations (37.2%, \( p < .001 \)), where the proportion of in-hospital screenings decreased from 38.2% to 30.8%. The recall rates increased in 2020, both in the in-hospital and outreach groups (\( p < .001 \)).

Data stratification by hierarchy of hospitals is presented in Fig. 1. The medical centers provided more screenings than other hospitals in both 2019 and 2020. During the pandemic, the number of screenings decreased more in medical centers. Fig. 2 shows the data stratification by age, and decrease of screening number and increase of outreach proportion occurred across nearly all age groups, with statistical examination showing that the difference of screenings in the two years were associated with age and the hierarchy of hospitals (\( p < .001 \)).

4. Discussion

Results for the nation-wide breast cancer screening program during the COVID-19 pandemic in Taiwan showed significant decrease in in-hospital screening while outreach with mobile mammography units maintained relatively stable services. There are several possible explanations for the in-hospital examination decrease. Firstly, restriction on hospital visits [8–9] and triage of patients with COVID-19 infection risks to outdoor visiting areas both limited the number of people entering hospitals. Secondly, people hesitated to go to hospitals during the pandemic. Thirdly, the hospitals did not promote cancer screening as actively as they did before the outbreak.

Accessibility is one of the important factors associated with breast cancer screening participation [10–12]. Outreach programs increase accessibility for community residents to receive a mammography. The data showed that with proper measures, community screening remained a safe and reliable way to maintain regular breast examinations during the pandemic.

The effect of COVID-19 on breast cancer screening was observed across all levels of hospitals and was more pronounced for medical centers. Because hospitals followed the direction of the Central Epidemic Command Center (CECC), they tended to have similar policies to prevent spread of infection; however, the medical centers might have stricter policies leading to higher degree of screening rate decline. Age is one of the influencing factors for women participating in breast cancer screening [13] or adhering to guidelines for screening mammography [14], and the data showed a similar degree of reduced screening participation across nearly all age groups. Although statistical significance is present, it might be due to the very large sample size in the study [15].

Healthcare practices have changed since the COVID-19 pandemic struck. Our report confirms that outreach services can maintain relatively stable breast cancer screening rates under this kind of public health crisis. In contrast to restriction of healthcare and cancer screening in the hospitals, building a flexible, outreach system into the community might need to be considered when policymakers are preparing for possible future pandemics.

| Table 1 |
| --- |
| Comparison of the number of screening mammograms and recall rates in the same period of 2019 and 2020. |

|          | Number of screenings | Recall rate | 2019 (Jan.–Apr.) | 2020 (Jan.–Apr.) | Difference | \( p \)-value |
|----------|----------------------|-------------|------------------|------------------|------------|--------------|
|          | Numbers              | Proportion  | Numbers          | Proportion       |            |              |
|          |                      |             | Total            | 396,371          | 100%       | -87,908 (-22.2%) | <0.001        |
|          |                      |             | In-hospital      | 151,343          | 38.2%      | -56,261 (-37.2%) | <0.001        |
|          |                      |             | Outreach         | 245,028          | 61.8%      | -31,647 (-12.9%) | <0.001        |
|          | Recall rate          |             | In-hospital      | 95,082           | 30.8%      | 213,381       | 69.2%         | 0.4% | <0.001        |
|          |                      |             | Outreach         | 6,6%             | 8.3%       | 6,9%          | 6.6%          | 0.3% | <0.001        |

\( ^a \) Two-sample test for proportion to examine the screening rate differences. We used the screening rate of 39.9% in 2018 to estimate the number of eligible women and presumed they are the same in 2019 and 2020. The calculation was made by using approximate values.

\( ^b \) Two-sample test for proportion to examine the recall rate differences.

\( ^c \) The proportion of in-hospital screenings decreased and the proportion of outreach increased in 2020. The difference was examined using Chi-square test and showed significant difference (\( p < .001 \)).
**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Ethical approval**

Ethical approval was not required for this study.

**Declaration of competing interest**

None.

**Acknowledgements**

We acknowledge Herg-Chia Chiu at the Department of Healthcare Administration and Medical Informatics of Kaohsiung
Medical University for helping to examine the data. We also thank the Center for Medical Informatics and Statistics of Kaohsiung Medical University for providing statistical support.

References

[1] Tabar L, Dean PB, Chen TH-H, Yen AM-F, Chen SL-S, Fann JC-Y, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 2019;125:515–23.

[2] Lai C-C, Shih T-F, Ko W-C, Tang H-J, Huieh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.

[3] Wilson R. COVID-19 sidelines breast cancer screening. Oncol Times 2020;42:14.

[4] Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in The Netherlands. Lancet Oncol 2020;21:750–1.

[5] Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing. J Am Med Assoc 2020;323:1341–2.

[6] Taiwan Centers for Disease Control. Taiwan centers for disease control homepage. https://www.cdc.gov.tw/ [Accessed 26 June 2020 in [Mandarin]].

[7] reportHealth promotion administration annual report 2019. English edition: p. 112. https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4159&pid=12398; Accessed 13 August 2020.

[8] Taiwan Centers for Disease Control. Principles of visitor restrictions at medical facilities in the time of COVID-19. 2020 [Mandarin]], https://www.mohw.gov.tw/cp-4635-51709-1.html. [Accessed 26 June 2020].

[9] Liu Y-A, Hsu Y-C, Lin M-H, Chang H-T, Chen T-J, Chou L-F, et al. Hospital visiting policies in the time of coronavirus disease 2019: a nationwide website survey in Taiwan. J Chin Med Assoc 2020;83:566–70.

[10] Yu MY, Wu TY. Factors influencing mammography screening of Chinese American women. J Obstet Gynecol Neonatal Nurs : J Obstet Gynecol Neonatal Nurs 2005;34:386–94.

[11] Patel K, Kanu M, Liu J, Bond B, Brown E, Williams E, et al. Factors influencing breast cancer screening in low-income African Americans in Tennessee. J Community Health 2014;39:943–50.

[12] Wu Z, Liu Y, Li X, Song B, Ni C, Lin F. Factors associated with breast cancer screening participation among women in mainland China: a systematic review. BMJ Open 2019;9. e028705-e.

[13] Lee K, Lim HT, Park SM. Factors associated with use of breast cancer screening services by women aged > 40 years in Korea: the third Korea national health and nutrition examination survey 2005 (KNHANES III). BMC Canc 2010;10:144.

[14] Rahman SMM, Dignan MB, Shelton BJ. Factors influencing adherence to guidelines for screening mammography among women aged 40 years and older. Ethn Dis 2003;13:477–84.

[15] Lin Jr M, HCL Shmueli G. Research commentary—too big to fail: large samples and the p-value problem. Inf Syst Res 2013;24:906–17.